Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model.

[1]  K. Kang,et al.  Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells , 2015, Oncotarget.

[2]  Lizhong Wang,et al.  FOXP3-microRNA-146-NF-κB as oncotarget , 2015, Oncoscience.

[3]  M. Junttila,et al.  Translational value of mouse models in oncology drug development , 2015, Nature Medicine.

[4]  Xiuping Liu,et al.  FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells. , 2015, Cancer research.

[5]  D. Frank,et al.  STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b , 2014, Cancers.

[6]  A. Richardson,et al.  STAT3 Induction of miR-146b Forms a Feedback Loop to Inhibit the NF-κB to IL-6 Signaling Axis and STAT3-Driven Cancer Phenotypes , 2014, Science Signaling.

[7]  E. Elinav,et al.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.

[8]  A. Palucka,et al.  Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.

[9]  J. Byrd,et al.  Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies , 2012, Clinical Cancer Research.

[10]  W. Hennink,et al.  Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[12]  A. Borowsky.  Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[13]  Laura J. Esserman,et al.  Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.

[14]  P. Forgez,et al.  Glucocorticoid receptor and breast cancer , 2011, Breast Cancer Research and Treatment.

[15]  R. Lidereau,et al.  Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers , 2011, EMBO molecular medicine.

[16]  Ana M. Aransay,et al.  miRanalyzer: an update on the detection and analysis of microRNAs in high-throughput sequencing experiments , 2011, Nucleic Acids Res..

[17]  K. Nicolay,et al.  Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  C. Gutiérrez,et al.  Dexamethasone upregulates FOXP3 expression without increasing regulatory activity. , 2011, Immunobiology.

[20]  V. Fuster,et al.  Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. , 2010, Molecular pharmaceutics.

[21]  Kazushi Inoue,et al.  MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer , 2009, Expert review of molecular diagnostics.

[22]  R. Schiffelers,et al.  Targeted delivery of anti-inflammatory agents to tumors. , 2009, Current pharmaceutical design.

[23]  R. Schiffelers,et al.  Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. , 2008, International journal of pharmaceutics.

[24]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[25]  D. DeFranco,et al.  Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. , 2008, Cancer research.

[26]  R. Schiffelers,et al.  Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  R. Schiffelers,et al.  Utility of Targeted Glucocorticoids in Cancer Therapy , 2008 .

[28]  R. Cardiff,et al.  Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. , 2006, Cancer research.

[29]  K. Livak,et al.  Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.

[30]  R. Schiffelers,et al.  Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. , 2005, Neoplasia.

[31]  C. Khanna,et al.  Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. , 2004, European journal of cancer.

[32]  M. Wauben,et al.  Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. , 2003, Arthritis and rheumatism.

[33]  S. Hundertmark,et al.  Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. , 1997, The Journal of endocrinology.

[34]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Langer,et al.  Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. , 1983, Science.

[36]  S. Fleischer,et al.  Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots , 1970, Lipids.

[37]  Chundong Yu,et al.  Associations of miR-146a and miR-146b expression and breast cancer in very young women. , 2015, Cancer biomarkers : section A of Disease markers.